BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2118879)

  • 41. Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial.
    Aulitzky WE; Tilg H; Gastl G; Mull R; Flener R; Vogel W; Herold M; Berger M; Judmaier G; Huber C
    Eur J Cancer; 1991; 27(4):462-7. PubMed ID: 1827721
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Raised levels of tumour necrosis factor-alpha and neopterin, but not interferon-alpha, in serum of HIV-1-infected patients from Ethiopia.
    Ayehunie S; Sonnerborg A; Yemane-Berhan T; Zewdie DW; Britton S; Strannegard O
    Clin Exp Immunol; 1993 Jan; 91(1):37-42. PubMed ID: 8419084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective induction of mononuclear phagocytes to produce neopterin by interferons.
    Bitterlich G; Szabó G; Werner ER; Larcher C; Fuchs D; Hausen A; Reibnegger G; Schulz TF; Troppmair J; Wachter H
    Immunobiology; 1988 Feb; 176(3):228-35. PubMed ID: 2452128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neopterin augmentation of tumor necrosis factor production.
    Barak M; Gruener N
    Immunol Lett; 1991 Sep; 30(1):101-6. PubMed ID: 1959936
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
    Ohno R; Yamaguchi Y; Toge T; Kinouchi T; Kotake T; Shibata M; Kiyohara Y; Ikeda S; Fukui I; Gohchi A; Sugiyama Y; Saji S; Hazama S; Oka M; Ohnishi K; Ohhashi Y; Tsukagoshi S; Taguchi T
    Clin Cancer Res; 2000 Jul; 6(7):2661-9. PubMed ID: 10914707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rapid cytokine release in cancer patients treated with interleukin-2.
    Weidmann E; Bergmann L; Stock J; Kirsten R; Mitrou PS
    J Immunother (1991); 1992 Aug; 12(2):123-31. PubMed ID: 1504053
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS).
    Troppmair J; Nachbaur K; Herold M; Aulitzky W; Tilg H; Gastl G; Bieling P; Kotlan B; Flener R; Mull B
    Clin Exp Immunol; 1988 Dec; 74(3):392-7. PubMed ID: 3148378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-dose gamma-interferon therapy is ineffective in renal cell carcinoma patients with large tumour burden.
    Aulitzky WE; Lerche J; Thews A; Lüttichau I; Jacobi N; Herold M; Aulitzky W; Peschel C; Stöckle M; Steinbach F
    Eur J Cancer; 1994; 30A(7):940-5. PubMed ID: 7946588
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Studies on the production of endogenous cytokines in patients with renal cell carcinoma].
    Nakashima J; Tachibana M; Baba S; Deguchi N; Jitsukawa S; Hata M; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1992 Jul; 83(7):1110-7. PubMed ID: 1507728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma.
    Smith JW; Urba WJ; Clark JW; Longo DL; Farrell M; Creekmore SP; Conlon KC; Jaffe H; Steis RG
    J Immunother (1991); 1991 Oct; 10(5):355-62. PubMed ID: 1790143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
    Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
    Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-related immunologic effects of levamisole in patients with cancer.
    Janik J; Kopp WC; Smith JW; Longo DL; Alvord WG; Sharfman WH; Fenton RG; Sznol M; Steis RG; Creekmore SP
    J Clin Oncol; 1993 Jan; 11(1):125-35. PubMed ID: 8418223
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interferon-gamma stimulates neopterin release from cultured kidney epithelial cells.
    Moutabarrik A; Takahara S; Nakanishi I; Kokado Y; Takano Y; Kameoka H; Ishibashi M; Zaid D
    Scand J Immunol; 1994 Jan; 39(1):27-30. PubMed ID: 8290891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha.
    Wiedermann CJ; Beimpold H; Herold M; Knapp E; Braunsteiner H
    J Am Coll Cardiol; 1993 Dec; 22(7):1897-901. PubMed ID: 8245346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
    Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
    J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
    Kroesen BJ; Buter J; Sleijfer DT; Janssen RA; van der Graaf WT; The TH; de Leij L; Mulder NH
    Br J Cancer; 1994 Oct; 70(4):652-61. PubMed ID: 7917912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytokine network and acute primary HIV-1 infection.
    Sinicco A; Biglino A; Sciandra M; Forno B; Pollono AM; Raiteri R; Gioannini P
    AIDS; 1993 Sep; 7(9):1167-72. PubMed ID: 8216972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Macrophage activation in vivax malaria: fever is associated with increased levels of neopterin and interferon-gamma.
    Brown AE; Teja-Isavadharm P; Webster HK
    Parasite Immunol; 1991 Nov; 13(6):673-9. PubMed ID: 1811217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients.
    Kurzrock R; Feinberg B; Talpaz M; Saks S; Gutterman JU
    J Interferon Res; 1989 Aug; 9(4):435-44. PubMed ID: 2502584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.